A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial

References

• Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 25: 1037–42
   Web of Science ®Google Scholar
• Lyytikainen O, Mentula S, Kononen E, Kotila S, Tarkka E, Anttila V, et al. First isolation of Clostridium difficile PCR ribotype 027 in Finland. Euro Surveill 2007; 12: E071108.2
   PubMedGoogle Scholar
• Johnson S, Gerding DN. Clostridium difficile-associated diarrhoea. Clin Infect Dis 1998; 26: 1027–34
   PubMed Web of Science ®Google Scholar
• Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, et al. Tolevamer, a novel non-antibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhoea. Clin Infect Dis 2006; 15: 411–20
   Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob Chemother 2007; 59: 705–10
   Web of Science ®Google Scholar
• Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758–64
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769–75
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J, Jr. Clostridium difficile-associated diarrhoea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459–77
   PubMed Web of Science ®Google Scholar
• Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867–8
   PubMed Web of Science ®Google Scholar
• Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhoea. Clin Infect Dis 2006; 43: 547–52
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhoea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846–8
   PubMed Web of Science ®Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012–7
   PubMed Web of Science ®Google Scholar
• Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35: 365–7
   PubMed Web of Science ®Google Scholar
• Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 1987; 6: 51–3
   PubMedGoogle Scholar
• Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in 6 patients. Lancet 1989; 333: 1156–60
   Google Scholar
• Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53: 882–4
   PubMed Web of Science ®Google Scholar
• Juang P, Skledar SJ, Zgheib NK, Paterson DL, Vergis EN, Shannon WD, et al. Clinical outcomes of intravenous immunoglobulin in severe Clostridium difficile-associated diarrhoea. Am J Infect Control 2007; 35: 131–7
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhoea. Gastroenterology 2005; 128: 764–70
   PubMed Web of Science ®Google Scholar
• Jorup-Ronstrom C, Hakanson A, Persson AK, Midtvedt T, Norin E. Faeces culture successful therapy in Clostridium difficile diarrhoea. Läkartidningen 2006; 103: 3603–5
   PubMedGoogle Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189–93
   PubMed Web of Science ®Google Scholar
• Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384–9
   PubMed Web of Science ®Google Scholar
• Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997; 41: 236–41
   PubMed Web of Science ®Google Scholar
• van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54: 197–205
   PubMed Web of Science ®Google Scholar
• Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56: 888–9
   PubMed Web of Science ®Google Scholar
• Young KW, Munro IC, Taylor SL, Veldkamp P, van Dissel JT. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 2007; 47: 317–26
   PubMed Web of Science ®Google Scholar